GH-axis / body-composition interest
CJC-1295 (with DAC) vs Ipamorelin
Both have human endocrine pharmacology, but neither has established lifestyle efficacy and their mechanisms/duration differ.
At a glance
CJC-1295 (with DAC)
Ipamorelin
Human evidence
Small early human studies show sustained GH and IGF-I elevation after CJC-1295 with DAC, establishing endocrine target engagement but not body-composition, recovery or anti-ageing efficacy.
Human evidence includes early PK/GH-response studies and a randomized Phase II postoperative-ileus trial. In that trial, IV ipamorelin 0.03 mg/kg twice daily did not significantly improve the primary or key secondary efficacy endpoints versus placebo.
Research focus
Growth-hormone axis research
GH-axis physiology and motility research
Regulatory status
Not FDA-approved; FDA lists CJC-1295 among substances with significant safety concerns in compounding.
Not FDA-approved; FDA lists safety concerns for compounded ipamorelin.
Route / formulation
CJC-1295 with DAC is not interchangeable with informal 'CJC without DAC' products.
The Phase II evidence was intravenous in postoperative patients and cannot be transferred to subcutaneous wellness/bodybuilding use.
No head-to-head outcome trial identified Both have human endocrine pharmacology, but neither has established lifestyle efficacy and their mechanisms/duration differ.